| News

Bright Peak secures investment of 107 million dollars

15.06.2021

Bright Peak has raised a total of 107 million US dollars as part of a financing round. The biotechnology firm manufactures proteins that do not exist in the natural world using a process of chemical synthesis. One of the proteins is now regarded as a highly promising candidate for cancer immunotherapy.

scientist making research in lab analyzing

Bright Peak Therapeutics, a biotechnology firm based in Basel and San Diego, California, has raised a total of 107 million US dollars following a successful Series B financing round, which was led by RA Capital. Among others, the seed investors Versant Ventures, a healthcare investment fund based in Silicon Valley, participated in the financing round. In fact, Versant Ventures had already invested 35 million dollars in Bright Peaks back in July of last year.

The internal research and development team at Bright Peak is based in Basel. The researchers, headed up by Jeffrey Bode, Professor of Synthetic Organic Chemistry at the Swiss Federal Institute of Technology in Zurich (ETH), and Vijaya Pattabiraman, Senior Vice-President and Chief Technology Officer, are intent on ushering in a new era of protein engineering, details of which can be found in a background report published by ETH. The team uses a process invented by Bode to synthesize peptides (KAHA ligation) with the aim of forming natural proteins, or more precisely cytokines, from scratch, so that they are more suitable as therapeutic agents. The overarching aim here is to develop new drugs.

“The investment from this accomplished crossover syndicate underscores the enthusiasm for our platform and re-affirms our commitment to transform the therapeutic utility of cytokines to treat people with cancer and autoimmune diseases”, comments Fredrik Wiklund, President and CEO of Bright Peak, in the company press release.

This platform, built over many years at ETH, allows proteins to be modified “as many times as we need to: once, five times or even a hundred times”, Bode explains. After having spent 20 years researching in this area, the first modified cytokine is now in mass production. More than 300 chemical steps were required to reach this stage. “Never before has such a sophisticated molecule been mass produced”, says Pattabiraman. Clinical trials are planned for this new molecule over the next year or two.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Botanikind settles in Basel
Basel Area Business & Innovation, Innovation, Invest

Botanikind settles in Basel

The internationally active Swiss company Botanikind has settled in Basel and established Botanikind AG there. It provides natural ingredients for...

Read More
Kinarus secures capital commitment of 57 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Kinarus secures capital commitment of 57 million Swiss francs

The biopharmaceutical company Kinarus has signed a capital commitment of up to 57 million Swiss francs with the investment group...

Read More
Biotech startups from the Basel Area confirm leading position
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Biotech startups from the Basel Area confirm leading position

As part of the Top 100 Swiss Startup Awards 2021, the most promising startups in Switzerland are honored. These also...

Read More
T3 Pharma wins Swiss Economic Award
Basel Area Business & Innovation, Innovation, Invest

T3 Pharma wins Swiss Economic Award

T3 Pharma has won the Swiss Economic Award 2021. Switzerland’s most prestigious young entrepreneur prize is awarded by the Swiss...

Read More
Worg selects Basel Area for European headquarters
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Worg selects Basel Area for European headquarters

Worg Pharmaceuticals has opted to establish its European headquarters at the site Allschwil of the Switzerland Innovation Park Basel Area....

Read More
ten23 health settles in Basel
Basel Area Business & Innovation, Innovation, Invest

ten23 health settles in Basel

The life sciences cluster Rosental Mitte located in Basel is home to a new, globally active company called ten23 health....

Read More
1 2 3 48

Do you have a question? We'd like to hear from you.